Parisa AOB, Mahmoud SHEKARI KHANIANI, Mohammadreza RANJOURI, Sima MANSOORI DERAKHSHAN

Molecular analysis and prevalence of Huntington disease in northwestern Iran

Background/aim: Huntington disease (HD) is a progressive adult-onset neurodegenerative disorder presenting an autosomal dominant inheritance. Since there is no information on the prevalence of HD in northwestern Iran, the aim of the present study was to determine the prevalence of HD and the number of CAG trinucleotide repeats in the population of northwestern Iran. Materials and methods: Genomic DNA was extracted from whole blood by the salting-out method. DNA samples were analyzed to determine the number of CAG trinucleotide repeats of the HD gene. An abnormally large number of CAG repeats, which is a diagnostic factor for the disease, was detected by polymerase chain reaction and agarose gel electrophoresis. Results: Out of 40 cases, we identified 14 nonkindred individuals with one expanded CAG allele at the IT15 gene. The frequency of the HD mutation in our group of patients was 35%. Expanded alleles varied from 36 to 70 CAG repeats, and normal alleles in HD patients varied from 20 to 26 CAG units. Conclusion: We found a significant correlation between age at onset of the disease and length of the expanded CAG tract: the lower the age, the longer the trinucleotide repeats length.

PDF

___

1. Heston LL, Folstein, SE. Huntingtons disease: a disorder of families. J Nerv Ment Dis 1991; 179: 512.
2. Group HsDCR. Huntingtons Disease Collaborative Research Group: A novel gene containing a trinucleotide repeat that is expanded and unstable in Huntingtons disease chromosomes. Cell 1993; 72: 971-983.
3. Kremer B, Goldberg P, Andrew SE, Theilmann J, Telenius H, Zeisler J, Squitieri F, Lin B, Bassett A, Almqvist E et al. A worldwide study of the Huntingtons disease mutation: the sensitivity and specificity of measuring CAG repeats. New Engl J Med 1994; 330: 1401-1406.
4. Andrew SE, Goldberg YP, Kremer B, Telenius H, Theilmann J, Adam S, Starr E, Squitieri F, Lin B, Kalchman MA et al. The relationship between trinucleotide (CAG) repeat length and clinical features of Huntingtons disease. Nat Genet 1993; 4: 398-403.
5. Rubinsztein DC, Leggo J, Coles R, Almqvist E, Biancalana V, Cassiman JJ, Chotai K, Connarty M, Craufurd D, Curtis A et al. Phenotypic characterization of individuals with 3040 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 3639 repeats. Am J Hum Genet 1996; 59: 16.
6. Sharp AH, Loev SJ, Schilling G, Li SH, Li XJ, Bao J, Wagster MV, Kotzuk JA, Steiner JP, Lo A et al. Widespread expression of Huntingtons disease gene (IT15) protein product. Neuron 1995; 14: 1065-1074.
7. Glass M, Dragunow M, Faull R. The pattern of neurodegeneration in Huntingtons disease: a comparative study of cannabinoid, dopamine, adenosine and GABA A receptor alterations in the human basal ganglia in Huntingtons disease. Neuroscience 2000; 97: 505-519.
8. Cattaneo E, Zuccato C, Tartari M. Normal huntingtin function: an alternative approach to Huntingtons disease. Nat Rev Neurosci 2005; 6: 919-930.
9. Li SH, Li XJ. Huntingtinprotein interactions and the pathogenesis of Huntingtons disease. Trends Genet 2004; 20: 146-154.
10. Mattson MP. Apoptosis in neurodegenerative disorders. Nat Rev Mol Cell Bio 2000; 1: 120-130.
11. Hickey MA, Chesselet MF. Apoptosis in Huntingtons disease. Prog Neuro-Psychoph 2003; 27: 255-265.
12. Hayden MR. Huntingtons chorea. Springer Science+Business Media 2012; 2: 15.
13. Paulsen JS. Cognitive impairment in Huntington disease: diagnosis and treatment. Curr Neurol Neurosci 2011; 11: 474- 483.
14. Roos RA. Huntingtons disease: a clinical review. Orphanet J Rare Dis 2010; 5: 40.
15. Ranen NG, Stine OC, Abbott MH, Sherr M, Codori AM, Franz ML, Chao NI, Chung AS, Pleasant N, Callahan C et al. Anticipation and instability of IT-15 (CAG)n repeats in parentoffspring pairs with Huntington disease. Am J Hum Genet 1995; 57: 593.
16. Wheeler VC, Persichetti F, McNeil SM, Mysore JS, Mysore SS, MacDonald ME, Myers RH, Gusella JF, Wexler NS. Factors associated with HD CAG repeat instability in Huntington disease. J Med Genet 2007; 44: 695-701.
17. Ross CA, Tabrizi SJ. Huntingtons disease: from molecular pathogenesis to clinical treatment. Lancet Neurol 2011; 10: 83- 98.
18. Myrianthopoulos NC. Huntingtons chorea. J Med Genet 1966; 3: 298.
19. Reed TE, Chandler JH. Huntingtons chorea in Michigan. I. Demography and genetics. Am J Hum Genet 1958; 10: 201.
20. Tyagi S, Tyagi LK, Shekhar R, Singh M, Kori M. Symptomatic treatment and management of Huntingtons disease: an overview. Global Journal of Pharmacology 2010; 4: 6-12.
21. Stevens DL. Heterozygote frequency for Huntingtons chorea. Adv Neurol 1973; 1: 191-208.
22. Myrianthopoulos N. Huntingtons chorea: the genetic problem five years later. Adv Neurol 1973; 1: 150.
23. Warner J, Barron L, Brock D. A new polymerase chain reaction (PCR) assay for the trinucleotide repeat that is unstable and expanded on Huntingtons disease chromosomes. Mol Cell Probe 1993; 7: 235-239.
24. Lima e Silva TC, Serra HG, Bertuzzo CS, Lopes-Cendes I. Molecular diagnosis of Huntington disease in Brazilian patients. Arq Neuro-Psiquiat 2000; 58: 11-17.
25. Pearson CE, Sinden RR. Trinucleotide repeat DNA structures: dynamic mutations from dynamic DNA. Curr Opin Struc Biol 1998; 8: 321-330.
26. Shao J, Diamond MI. Polyglutamine diseases: emerging concepts in pathogenesis and therapy. Hum Mol Genet 2007; 16: R115-R123.
27. Zoghbi HY, Orr HT. Glutamine repeats and neurodegeneration. Annu Rev Neurosci 2000; 23: 217-247.
28. Hormozian F, Houshmand M, Sanati M, Ghiasvand R, Banoie M. Molecular analysis of the (CAG)N repeat causing Huntingtons disease in 34 Iranian families. Indian Journal of Human Genetics 2004; 10: 53.
29. Leeflang EP, Tavaré S, Marjoram P, Neal CO, Srinidhi J, MacFarlane H, MacDonald ME, Gusella JF, de Young M, Wexler NS et al. Analysis of germline mutation spectra at the Huntingtons disease locus supports a mitotic mutation mechanism. Hum Mol Genet 1999; 8: 173-183.